You are here: Industry Insights > Ipsen

News List

Ipsen warns over medicine supplies amid Brexit uncertainty pharmaphorum
December 17, 2018
France’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma industry and patients’ access to medicines.
Exelixis and Ipsen Initiate Phase 3 Pivotal Trial for Advanced Hepatocellular Carcinoma Treatment americanpharmaceuticalreview
December 06, 2018
Evelix’s, Inc. and Ipsen have announced the initiation of COSMIC-312, a phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with.....
Ipsen’s Cabometyx wins EU nod for liver cancer pharmatimes
November 19, 2018
Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.
Japanese regulators grant additional approval for the sale of Ipsen's rare cancer drug in Japan biospectrumasia
November 16, 2018
The drug was developed by French drug firm Ipsen and is approved in Japan for the treatment of acromegaly and pituitary gigantism since 2012
Ipsen reveals positive Phase 2 data of Cabometyx in liver cancer pharmafile
July 06, 2018
French pharmaceutical company Ipsen has announced that The New England Journal of Medicine has published the results of a Phase II clinical trial of liver cancer drug Cabometyx (cabozantinib).
Ipsen moves U.S. headquarters to Kendall Square fiercebiotech
June 11, 2018
Ipsen is moving its U.S. headquarters to Kendall Square in Cambridge, Massachusetts. The French drugmaker is the latest in a series of European companies to pick the biotech hotspot as their U.S. base.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership firstwordpharma
May 30, 2018
Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group, and The University of Texas MD Anderson Cancer Center today announced a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by research
Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx®, for Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) biospace
March 29, 2018
Ipsen today announced that the EMA, the European regulatory authority, has validated the filing of a new application for an additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).
Japanese regulators grant additional approval for the sale of Ipsen's rare cancer drug in Japan biospectrumasia
July 05, 2017
The drug was developed by French drug firm Ipsen and is approved in Japan for the treatment of acromegaly and pituitary gigantism since 2012
Ipsen and Saol partner to co-promote Dysport in US pharmaceutical-technology
July 04, 2017
The US affiliate of French pharmaceutical company Ipsen has entered an exclusive, three-year agreement with Saol Therapeutics to promote Dysport (abobotulinumtoxinA) for approved therapeutic indications in adult spasticity and pediatric lower limb spastic

Previous page 1 2 3 Next page